243PD Phase 3 Study of Radium-223 Dichloride (Ra-223) in Asian Patients (pts) with Castration-Resistant Prostate Cancer (CRPC) and Symptomatic Bone Metastases (Mets)
Y. Sun,H. Shi,C. -H. Chen,J. L. Lee,T. W. Kang,S. H. Park,T. L. Wu,Q. S. Ng,B. Keam,S. C. A. Wong,M. H. Tay,Q. Ding,F. Li,D. C. E. Ng,X. Liu,Z. Zhang,J. Guo
DOI: https://doi.org/10.1093/annonc/mdv524.08
IF: 51.769
2015-01-01
Annals of Oncology
Abstract:Aim/Background: Ra-223 is approved for pts with CRPC, symptomatic bone mets, and no visceral mets. This study evaluated efficacy and safety of Ra-223 + best standard of care (BSoC) in Asian pts with CRPC and symptomatic bone mets. Methods: These are interim results of Ra-223 effect on total alkaline phosphatase (tALP) and prostate-specific antigen (PSA) dynamics, pharmacokinetics (PK) in a Chinese pt subset, and safety. Pts had progressive, symptomatic CRPC, ≥2 bone mets, no visceral mets, and were docetaxel ineligible. Pts were to have 6 injections (inj) Ra-223 (50 kBq/kg IV) q4wk × 6 + BSoC. Blood samples for clinical chemistry were assessed ≤2 d pre-inj. Primary efficacy was tALP % change from baseline at 12 wk. tALP and PSA response and normalization were also reported. PK blood samples came from a Chinese pt subset up to 72 h after first dose. Safety included adverse events (AEs). Results: At data cutoff, 115 pts were enrolled; 70 had ≥1 inj; 15 discontinued treatment (tx) early. 9 pts (valid PK data) were in the PK analysis. Table shows mean % changes in tALP and PSA from baseline at 12 wk, and tALP and PSA response and normalization. 24% and 3% pts had ≥50% decreases in tALP and PSA, respectively. Radioactivity cleared rapidly after 1 Ra-223 dose; fraction of remaining activity decreased: 14.5 ± 6.4% at 15 min to 0.4 ± 0.4% at 72 h. Geometric mean (coefficient of variation, %) of Ra-223 AUC(0-last) was 0.456 kBq*h/mL (82%); Ra-223 Cmax was 0.263 kBq/mL (33%). Most common tx-related AEs (>5%) were nausea, anemia, diarrhea, vomiting, decreased appetite, and decreased platelets.TabletALPtALPPSAPSAMean % change, baseline to 12 wkLOCF*Last observation carried forward; pts with nonmissing baseline values N = 70OC†Observed case; pts with nonmissing values, baseline & wk 12 N = 33LOCF*Last observation carried forward; pts with nonmissing baseline values N = 70OC†Observed case; pts with nonmissing values, baseline & wk 12 N = 33Mean (SD)-23.9 (30.1)-28.4 (28.3)85.68 (143.28)91.42 (135.55)Response (changes ≤12 wk‡Max tALP decrease after tx; decrease confirmed ∼ ≥ 4 wk later), N = 70Decrease vs baseline, n (%)≥30%35 (50.0)35 (50.0)5 (7.1)5 (7.1)≥50%17 (24.3)17 (24.3)2 (2.9)2 (2.9)Confirmed decrease vs baseline, n (%)≥30%22 (31.4)22 (31.4)2 (2.9)2 (2.9)≥50%8 (114.3)8 (114.3)1 (1.4)1 (1.4)Normalization§Normal range at 12 wk (2 consecutive measurements, ≥2 wk apart) after tx start if baseline value > upper limits of normal., N = 40n (%)8 (20.0)8 (20.0)Not applicableNot applicable* Last observation carried forward; pts with nonmissing baseline values† Observed case; pts with nonmissing values, baseline & wk 12‡ Max tALP decrease after tx; decrease confirmed ∼ ≥ 4 wk later§ Normal range at 12 wk (2 consecutive measurements, ≥2 wk apart) after tx start if baseline value > upper limits of normal. Open table in a new tab Conclusions: Ra-223 decreased serum markers of CRPC activity. Radioactivity cleared rapidly from blood. Ra-223 PK data in 9 Chinese pts were in line with early phase 1 results. Ra-223 was safe and well tolerated. Clinical trial identification: NCT01810770 Disclosure: T.L. Wu: ownership interest in Pfizer. Q.S. Ng: served on the Advisory Board for Bayer. M.H. Tay: honoraria from Bayer for attending an advisory board meeting. D.C.E. Ng: research funding from Bayer, as principal investigator of Bayer-sponsored trials. X. Liu, Z. Zhang: employed by Bayer HealthCare Company Ltd. All other authors have declared no conflicts of interest.